Vertex Pharmaceuticals Inc (VRTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
VRTX price, last 12 months
Key stats
- Previous close
- $536.45
- Open
- $537.79
- Day range
- $517.82 – $537.79
- 52-week range
- $412.27 – $568.67
- Volume
- 1.2M
- Avg volume (20 days)
- 1.5M
- Market cap
- $136.6B
Performance
Technicals and fundamentals
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $136.6B